GENE ONLINE|News &
Opinion
Blog

2022-03-04| Partner

The 2022 UK-Taiwan Digital Health Programme, Linking the Medical and Technology Strength of the UK and Taiwan!

by Aurora Mau
Share To

The 2022 UK-Taiwan Digital Health Programme offers valuable insights and B2B matchmaking opportunities into Taiwan’s digital health sector for both Taiwan and UK organizations. 

In the 2022 UK-Taiwan Digital Health B2B Matchmaking, selected British and Taiwanese organizations in ICT, VC, Medical AIoT, MedTech, and research academia will be able to link with potential commercial partners, and further consolidate prospective collaborations to innovate the life science and digital healthcare industry. 

GeneOnline has handpicked several household names from Taiwan that will be attending the B2B Matchmaking:

 

ICT (Information and Communications Technology)

 

The advanced ICT in Taiwan is top-class worldwide. With its applications in the healthcare and life science industry, ICT has become one of the strengths of Taiwan’s digital health industry. Digital Health providers are able to optimize the manufacturing process and innovate digital health products integrating Taiwan’s ICT.

ASUS, a Taiwanese multinational computer and hardware company, has developed a new range of holistic smart-healthcare devices and services for cardiovascular disease and more efficient outpatient clinic, including ASUS portable ultrasound series, a scanner that integrates seamlessly via mobile app or web platform, and ASUS intelligent telemedicine cart, a mobile nursing station combining ASUS medical computer, network communication equipment, and wide-ranging I/O interfaces.

BenQ Materials Corporation is a Taiwanese multinational company that has dominated the markets of technology products, consumer electronics, computing, and communications devices in APAC. BenQ also is dedicated to developing high-quality and innovative medical devices, equipment, consumables, and solutions for major medical institutions and professionals worldwide. 

 

Biotech

 

As the pandemic struck in 2020, market demand for smart diagnosis and treatment, along with pandemic prevention, ballooned in the digital health industry. 

Taiwan’s electronics manufacturing industry has been transforming tremendously in recent years, in order to create a zero contact, non-invasive system for medical providers. On top of that, Taiwan’s biotech industry R&D has performed exceptionally well in the development of therapeutic drugs, tests, and vaccines.

GeneOnline has listed 3 outstanding Taiwanese biotech companies that put in great effort in developing medical research related devices and instruments: 

 

Phalanx Biotech Group is a strategic spin-off from the collaborative biotech effort of the Ministry of Economic Affairs (MOEA) and Industrial Technology Research Institute (ITRI). As one of the global four microarray developers, Phalanx is dedicated to developing, manufacturing, and providing services related to microarrays. The company also carries genomics services in clinical applications. 

DELBio, a member of the Delta Group, manufactures a selection of professional ODM and OEM in In-Vitro Diagnostics instruments. DELBio’s R&D Team focuses on the research platforms of diabetes care, respiratory care, and a variety of diagnostic systems.

ORIGEM biotech, a startup company founded in 2016, provides smart microfluidic solutions for biomedical experiments, including single-cell capture and culture devices to assist medical researchers in optimizing their workflow. Aside from microfluidic chips, ORIGEM also sets up a platform that integrates medical, biology, and semiconductor.

 

Healthcare Service Providers

 

With the up-to-date smart medical system provided by the National Health Insurance Administration (NHI), there is no doubt the digital healthcare service is thriving in Taiwan’s hospitals, clinics, and markets. GeneOnline has selected 5 companies in alphabetical order with outstanding digital healthcare services or smart medical devices/solutions.

ACE Biotek focuses on deploying technologies designed for healthier living and better medical care by utilizing artificial intelligence, image-enhancing algorithms, cloud computing, and terahertz technology. With its strength in smart healthcare, the company provides smart medical solutions regarding imaging algorithms, cloud computing, and artificial intelligence for the early diagnosis of diseases.

CancerFree Biotech is a startup company dedicated to personalizing treatment for cancer. With the focus on the analysis of circulating tumor cells (CTCs), The company specializes in personalized analysis using circulating tumor cell culture by forming organoid systems that help doctors and patients develop the optimal treatment strategy to fight cancer.

Deep01 is a software company developing advanced AI-based SaMD (Software as a Medical Device) for decision support that aims to empower emergency physicians to expedite patient treatment. Their technology is able to analyze brain CT imaging and provide smart solutions for assisting ER physicians with prioritizing the time-sensitive and life-threatening cases in the golden hour.

iXensor is a new generation health technology company. The company has integrated medical engineering, biochemistry, and information technology to develop the PixoTech platform, the blood glucose monitoring system for connected smart healthcare. With its lab-grade mobile medical diagnostics, the PixoTech platform is the world’s first FDA-approved smartphone camera-based blood test system. 

WASAI Technology, based in Taiwan, aims to deliver acceleration technologies of High-Performance Data Analysis (HPDA) in future data centers for targeted vertical applications with massive volumes and high velocities of scientific data. With the all-in-one DNA sequence solution, WASAI Technology aims to contribute to the development of precision medicine with the high-end integration technology and the mature hardware environment in Taiwan.

Taiwan’s digital health market has not hit max saturation and is expected to grow in the coming years. More innovative service and solution providers from Taiwan will be joining the event. Many of them come equipped with cutting-edge and creative technology waiting to set foot in a larger and global market. 

 

Academia & Healthcare Service

 

Clinical and medical research academia provides digital healthcare with a more research-oriented and science-grounded way to innovate the life science industry. The hospitals, on the other hand, stand at the forefront leading the digitalized transformation in the healthcare industry such as innovating the health system and infrastructure to provide better patient care. 

Some of the well-known medical universities and hospitals in Taiwan such as National Central University, Chun Yuan Christian University, Kaohsiung Medical University, and Taichung Veterans General Hospital and more will be joining the B2B Matchmaking, looking for opportunities to collaborate with UK digital health service providers to optimize their service and research development.

 

Investors & Venture Capitals

 

Taiwan’s healthcare investors and venture capitals are looking for potential partners to invest and develop strategic partnerships in the future of digital healthcare around the globe.

Taiwania Capital, venture capital with the government arm and backed, is looking to nurture the broader startup ecosystem and scout potential industries mainly focused on technology and biotech. 

Invest Taipei Office (ITO), the organization assists domestic and overseas companies by providing knowledge and understanding of Taipei’s business environment. Not only does ITO assist companies with a variety of requirements for setting up businesses in Taipei city, the company also offers consulting, introduction, and resource consolidation services, as well as investment troubleshooting.

 

 

The 2022 UK-Taiwan Digital Health B2B Matchmaking is still open for like-minded organizations to register. Visit the link to register: https://mailchi.mp/geneonline.com/uk-taiwan-digital-health

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Biotech Showcase 2023: Digital Medicine Innovation: Its Time is Now
2023-02-01
MedTex Summit Asia 2022: Revolutionizing Smart Healthcare with Next Generation Technologies
2022-12-09
Monkeypox Cases Fall In The UK But A New Strain Of The Disease Emerges
2022-09-02
LATEST
Innovative Cellular Mapping of BRCA-Related Breast Cancer Findings Reveals Novel Therapeutic Targets
2024-03-29
Previewing AACR 2024 With Select Pre-Meeting Highlights
2024-03-28
Roche Delivering on Malaria Screening Solutions for Blood Donation
2024-03-28
Innovating Cancer Treatment: The Role of ADC Technology at Nona Biosciences
2024-03-28
BIO CHINA 2024 Brings Biotech Experts and Industry Elites Together for Innovation
2024-03-27
Galderma’s Strong European IPO Debut
2024-03-26
Markets and Mergers: Boston Scientific and Axonics Shake Hands on Deal
2024-03-25
EVENT
2024-04-06
Biotech Innovation Funding Networking
Los Angeles, USA
Scroll to Top